Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 10, 2013 08:30 ET | Source: Immunomedics, Inc.

Immunomedics Develops T-Cell Redirecting Bispecific Antibodies as Potential Therapeutics for Solid and Liquid Tumors

WASHINGTON, April 10, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted...
April 09, 2013 08:30 ET | Source: Immunomedics, Inc.

Immunomedics Reports First Results of Labetuzumab-SN-38 in Colorectal Cancer

WASHINGTON, April 9, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted...
April 08, 2013 16:30 ET | Source: Immunomedics, Inc.

Immunomedics Creates Novel Antibody-Cytokine Conjugates for Cancer Therapy

-- Preclinical Study Presented at 2013 Annual Meeting of the American Association for Cancer Research (AACR) -- -- Study on Mechanism of Cancer Metastasis also Reported -- WASHINGTON, April...
April 08, 2013 13:00 ET | Source: Immunomedics, Inc.

Immunomedics Announces Clivatuzumab-Based Blood Test Can Differentiate Between Pancreatic Cancer and Chronic Pancreatitis

WASHINGTON, April 8, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted...
April 01, 2013 17:01 ET | Source: Immunomedics, Inc.

Immunomedics Settles Finra Arbitration Proceedings Relating to Its Prior Investment in Certain Securities

MORRIS PLAINS, N.J., April 1, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...
April 01, 2013 08:30 ET | Source: Immunomedics, Inc.

Immunomedics Announces Presentations at the 2013 Annual Meeting of the American Association for Cancer Research

MORRIS PLAINS, N.J., April 1, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...
February 27, 2013 16:01 ET | Source: Immunomedics, Inc.

Immunomedics Announces Closing of Public Offering and Full Exercise of Overallotment Option by Underwriters

MORRIS PLAINS, N.J., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...
February 25, 2013 08:30 ET | Source: Immunomedics, Inc.

Immunomedics to Present at Cowen and Company 33rd Annual Health Care Conference

MORRIS PLAINS, N.J., Feb. 25, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...
February 22, 2013 09:20 ET | Source: Immunomedics, Inc.

Immunomedics Prices $14.0 Million Public Offering of Common Stock

MORRIS PLAINS, N.J., Feb. 22, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...
February 21, 2013 16:01 ET | Source: Immunomedics, Inc.

Immunomedics Announces Proposed Public Offering of Common Stock

MORRIS PLAINS, N.J., Feb. 21, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...